Schroder UK Public Private Trust PLC - London-based investment trust - Makes £2.7 million investment in antibody-drug conjugates development company, Araris Biotech AG, as part of its £21.4 million financing round.

Araris is developing an antibody-drug conjugate-linker technology to allow for the efficient and precise production of ADCs.

Portfolio Managers Tim Creed and Roger Doig say: ‘Araris is the tenth new investment and the second therapeutics-focused private equity investment since our appointment as Portfolio Manager. This investment is in line with the company’s private equity sub-strategy for backing innovative life sciences businesses, at the clinical or near-clinical stage, with high-quality science, a strong financing position, alongside high-quality co-investors.’

Current stock price: 15.86 pence, down 2.3% on Friday

12-month change: down 53%

Copyright 2022 Alliance News Limited. All Rights Reserved.